Immunotherapy & Oncology
Cancer treatment has moved from poisoning dividing cells towards directing the immune system at the tumour, and towards drugs that carry their payload only to cancerous tissue. It absorbs more drug development spending than any other area.
388 stocks
| # | Name | Holding | Trade Value |
Theme Stocks |
% of Portfolio | Status | |
|---|---|---|---|---|---|---|---|
| 601 |
NPA
Nichols & Pratt Advisers
Boston,
Massachusetts
| $185M | -$2.5M | 7 | 11.23% | Reduced |
|
| 602 |
UMB Bank
Kansas City,
Missouri
| $184M | +$237K | 34 | 2.33% | Increased |
|
| 603 |
OpenArc Corporate Advisory
Atlanta,
Georgia
| $183M | +$13.8M | 19 | 2.18% | Increased |
|
| 604 |
Citizens Financial Group
Providence,
Rhode Island
| $183M | +$17.3M | 14 | 2.2% | Increased |
|
| 605 |
XTX Topco
George Town,
Cayman Islands
| $183M | +$12.3M | 161 | 2.37% | Increased |
|
| 606 |
General Atlantic
New York
| $183M | -$80.7M | 3 | 6.28% | Reduced |
|
| 607 |
Homestead Advisers
Arlington,
Virginia
| $182M | +$16.3M | 4 | 4.53% | Increased |
|
| 608 |
Avanza Fonder
Stockholm,
Sweden
| $182M | +$7.19M | 9 | 3.97% | Increased |
|
| 609 |
Canoe Financial
Calgary,
Alberta, Canada
| $182M | +$284K | 1 | 2.25% | Increased |
|
| 610 |
DCM
DAFNA Capital Management
Los Angeles,
California
| $181M | -$20.9M | 25 | 34.58% | Reduced |
|
| 611 |
SCM
Squadron Capital Management
Westmont,
Illinois
| $180M | +$14.6M | 10 | 55.91% | Increased |
|
| 612 |
Tema ETFs
New York
| $180M | +$7.54M | 44 | 5.82% | Increased |
|
| 613 |
VV
Verity & Verity
Beaufort,
South Carolina
| $180M | +$917K | 7 | 12.36% | Increased |
|
| 614 |
Becker Capital Management
Portland,
Oregon
| $180M | -$1.18M | 9 | 4.83% | Reduced |
|
| 615 |
S
Sanofi
Paris,
France
| $179M | $0 | 3 | 33.46% | Maintained |
|
| 616 |
Reinhart Partners
Mequon,
Wisconsin
| $177M | +$3.21M | 1 | 4.05% | Increased |
|
| 617 |
Quilter Plc
London,
United Kingdom
| $177M | -$115K | 6 | 2.66% | Reduced |
|
| 618 |
Vestmark Advisory Solutions
Wakefield,
Massachusetts
| $177M | +$3.15M | 23 | 1.66% | Increased |
|
| 619 |
Grimes & Company
Westborough,
Massachusetts
| $176M | -$2.14M | 14 | 3.82% | Reduced |
|
| 620 |
John W. Bristol & Co
New York
| $176M | -$1.4M | 2 | 2.6% | Reduced |
|
| 621 |
VP
venBio Partners
San Francisco,
California
| $176M | +$142M | 3 | 33.8% | Increased |
|
| 622 |
SFM
Sphera Funds Management
Tel Aviv,
Israel
| $175M | +$24.2M | 29 | 22.86% | Increased |
|
| 623 |
Gabelli Funds
Rye,
New York
| $174M | -$39M | 23 | 1.11% | Reduced |
|
| 624 |
Aware Super
Sydney,
Australia
| $173M | -$5.17M | 8 | 2.45% | Reduced |
|
| 625 |
Emerald Advisers
Leola,
Pennsylvania
| $173M | -$38.6M | 5 | 4.06% | Reduced |
|